Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Virological responses in chronic hepatitis C patients undergoing prolonged therapy with low-dose Peg-IFNα-2a.

Hepato-gastroenterology - 1 Jan 2000

Zhou Jun-Ying, Jiang Zhi-An, Zhou Dong-Fang, Xing Wen-Li, Wang Wei, Wang Ya-Dong

Abstract excerpt

BACKGROUND/AIMS: Standard dose therapy with pegylated interferon α-2a (Peg-IFNα-2a) and ribavirin is not suitable for all patients because of the side effects. This study aims to evaluate the virological responses of low-dose but long-course Peg-IFNα-2a therapy compared with standard therapy. MET...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antiviral Agents
Share to Hepatitis C

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Polyethylene Glycols

Share to Recombinant Proteins

Share to RNA, Viral

Source

Identifiers

PMID: 23160168
DOI: 10.5754/hge12272

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Prepared record publication-23160168-2026-09-05.1. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Virological responses in chronic hepatitis C patients undergoing prolonged therapy with low-dose Peg-IFNα-2a.PMID 23160168Read ↗

The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis C patients with genotype 1.Semantic proximity Read ↗

[Short-term therapy with pegylated interferon plus ribavirin for the chronic hepatitis C genotype 2 patients].Semantic proximity Read ↗

Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial.Semantic proximity Read ↗

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.Semantic proximity Read ↗

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.Semantic proximity Read ↗

Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b.Semantic proximity Read ↗

Outcome of antiviral treatment in patients with chronic genotype 1 HCV hepatitis. A retrospective study in 507 patients.Semantic proximity Read ↗

Peginterferon and ribavirin treatment for hepatitis C virus infection.Semantic proximity Read ↗

Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.Semantic proximity Read ↗

Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.Semantic proximity Read ↗

New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.Semantic proximity Read ↗

The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.